JP2023549341A - Ｂｒｍ標的化化合物及び関連する使用方法 - Google Patents

Ｂｒｍ標的化化合物及び関連する使用方法 Download PDF

Info

Publication number
JP2023549341A
JP2023549341A JP2023527451A JP2023527451A JP2023549341A JP 2023549341 A JP2023549341 A JP 2023549341A JP 2023527451 A JP2023527451 A JP 2023527451A JP 2023527451 A JP2023527451 A JP 2023527451A JP 2023549341 A JP2023549341 A JP 2023549341A
Authority
JP
Japan
Prior art keywords
pyrazino
methyl
hydroxyphenyl
piperidin
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527451A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549341A5 (enExample
Inventor
ルー，リアン
ポール コームズ，アンドリュー
ハワード バッシュ，コリー
シェティ，ルパ
ダイ，チャオフォン
ラソール バーシュ，クレア
エイ ローズ，ジョン
ジュリー ビーム ロス，ダニエル
メイ，ソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prelude Therapeutics Inc
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of JP2023549341A publication Critical patent/JP2023549341A/ja
Publication of JP2023549341A5 publication Critical patent/JP2023549341A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2023527451A 2020-11-06 2021-11-08 Ｂｒｍ標的化化合物及び関連する使用方法 Pending JP2023549341A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110688P 2020-11-06 2020-11-06
US63/110,688 2020-11-06
PCT/US2021/058424 WO2022099117A1 (en) 2020-11-06 2021-11-08 Brm targeting compounds and associated methods of use

Publications (2)

Publication Number Publication Date
JP2023549341A true JP2023549341A (ja) 2023-11-24
JP2023549341A5 JP2023549341A5 (enExample) 2024-11-18

Family

ID=81456756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527451A Pending JP2023549341A (ja) 2020-11-06 2021-11-08 Ｂｒｍ標的化化合物及び関連する使用方法

Country Status (10)

Country Link
US (1) US12448389B2 (enExample)
EP (1) EP4240743A1 (enExample)
JP (1) JP2023549341A (enExample)
KR (1) KR20230117577A (enExample)
CN (1) CN116745295A (enExample)
AU (1) AU2021376415A1 (enExample)
CA (1) CA3200685A1 (enExample)
IL (1) IL302669A (enExample)
MX (1) MX2023005301A (enExample)
WO (1) WO2022099117A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023529908A (ja) * 2020-06-09 2023-07-12 プレリュード・セラピューティクス・インコーポレイテッド Ｂｒｍ標的化化合物及び関連する使用方法
JP2023551187A (ja) * 2020-11-20 2023-12-07 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024512501A (ja) 2021-03-19 2024-03-19 アルヴィナス・オペレーションズ・インコーポレイテッド インダゾール系化合物及び関連使用方法
CA3235512A1 (en) * 2021-10-22 2023-04-27 Xiaobao Yang Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applications
WO2023178181A1 (en) * 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2023269778A1 (en) * 2022-05-10 2024-12-12 Prelude Therapeutics Incorporated 6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 protein degraders for the treatment of cancer
CN120282966A (zh) * 2022-09-15 2025-07-08 普莱鲁德疗法有限公司 Brm靶向化合物和相关使用方法
JP2025538228A (ja) 2022-11-15 2025-11-26 プレリュード・セラピューティクス・インコーポレイテッド Ｂｒｍ標的化化合物及び関連する使用方法
WO2024192064A1 (en) * 2023-03-14 2024-09-19 Oncopia Therapeutics, Inc. D/B/A/ Proteovant Therapeutics, Inc. Compounds and compositions as smarca2/4 degraders and uses thereof
WO2024208300A1 (zh) * 2023-04-07 2024-10-10 南京再明医药有限公司 Brm选择性降解剂化合物
EP4695250A1 (en) 2023-04-12 2026-02-18 Aurigene Oncology Limited Tetracyclic compounds as smarca2 and/or smarca4 degraders
EP4727541A2 (en) * 2023-06-16 2026-04-22 Plexium, Inc. Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a
TW202515874A (zh) 2023-09-28 2025-04-16 美商亞文納營運公司 用於靶向降解富含白胺酸之重複激酶２（ｌｒｒｋ２）的基於苯并咪唑及苯并咪唑酮之ｐｒｏｔａｃ化合物
WO2025101738A1 (en) * 2023-11-07 2025-05-15 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
WO2025106472A1 (en) * 2023-11-13 2025-05-22 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 degraders and uses thereof
WO2025106482A1 (en) * 2023-11-13 2025-05-22 Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs Compounds and compositions as smarca2/4 degraders and uses thereof
WO2025113460A1 (zh) * 2023-11-28 2025-06-05 西藏海思科制药有限公司 一种哒嗪并三环衍生物及其在医药上的应用
CN120548310A (zh) * 2023-12-26 2025-08-26 标新生物医药科技(上海)有限公司 具有双氮杂环取代的异吲哚啉酮骨架的化合物及其应用
WO2025184459A1 (en) * 2024-03-01 2025-09-04 Prelude Therapeutics Incorporated Brm and brg1 targeting compounds and associated methods of use
US20250276074A1 (en) 2024-03-01 2025-09-04 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
WO2025194405A1 (en) * 2024-03-21 2025-09-25 Prelude Therapeutics Incorporated Polymorphic smarca inhibitors and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502097A (ja) * 2014-12-23 2018-01-25 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
WO2019195201A1 (en) * 2018-04-01 2019-10-10 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
WO2019207538A1 (en) * 2018-04-26 2019-10-31 Aurigene Discovery Technologies Limited Pyridazine derivatives as smarca2/4 degraders
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)
WO2020010227A1 (en) * 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
GB2554071A (en) 2016-09-14 2018-03-28 Univ Dundee Small molecules
CN110506039A (zh) 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
BR112019011200B1 (pt) 2016-12-01 2021-12-28 Arvinas Operations, Inc Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
WO2019084026A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
MX2021004191A (es) 2018-10-15 2021-05-27 Nurix Therapeutics Inc Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
CN115867554B (zh) 2020-06-09 2025-09-02 普莱鲁德疗法有限公司 Brm靶向化合物和相关使用方法
AU2023269778A1 (en) * 2022-05-10 2024-12-12 Prelude Therapeutics Incorporated 6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 protein degraders for the treatment of cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502097A (ja) * 2014-12-23 2018-01-25 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
WO2019195201A1 (en) * 2018-04-01 2019-10-10 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
WO2019207538A1 (en) * 2018-04-26 2019-10-31 Aurigene Discovery Technologies Limited Pyridazine derivatives as smarca2/4 degraders
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)
WO2020010227A1 (en) * 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023529908A (ja) * 2020-06-09 2023-07-12 プレリュード・セラピューティクス・インコーポレイテッド Ｂｒｍ標的化化合物及び関連する使用方法
JP2023551187A (ja) * 2020-11-20 2023-12-07 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
JP7723743B2 (ja) 2020-11-20 2025-08-14 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用

Also Published As

Publication number Publication date
AU2021376415A9 (en) 2025-01-09
AU2021376415A1 (en) 2023-06-22
EP4240743A1 (en) 2023-09-13
WO2022099117A1 (en) 2022-05-12
MX2023005301A (es) 2023-07-18
CN116745295A (zh) 2023-09-12
IL302669A (en) 2023-07-01
US20230083376A1 (en) 2023-03-16
CA3200685A1 (en) 2022-05-12
KR20230117577A (ko) 2023-08-08
US12448389B2 (en) 2025-10-21

Similar Documents

Publication Publication Date Title
US12448389B2 (en) BRM targeting compounds and associated methods of use
EP4506035A2 (en) Shp2 phosphatase inhibitors and methods of use thereof
AU2021289730A1 (en) BRM targeting compounds and associated methods of use
US20230365576A1 (en) BRM Targeting Compounds And Associated Methods Of Use
AU2021401403A1 (en) Cdk inhibitors and their use as pharmaceuticals
CN120418251A (zh) Brm靶向化合物和相关使用方法
AU2023295547A1 (en) Kat6 targeting compounds with ubiquitin ligase binding moiety
WO2023067355A1 (en) Heterocyclic compounds for use in the treatment of cancer
EA052189B1 (ru) Соединения, нацеленные на brm, и связанные с ними способы использования
WO2025101738A1 (en) Brm targeting compounds and associated methods of use
HK40128204A (en) Brm targeting compounds and associated methods of use
EA050130B1 (ru) Ингибиторы cdk и их применение в качестве лекарственных препаратов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260330